Treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus

International Journal of Antimicrobial Agents

Volumn 30, Issue 1, 2007, Pages 19-24

  Ferrara, Anna M ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Glycopeptides; MRSA; New antibacterials; Nosocomial pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; AZTREONAM; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; STREPTOGRAMIN DERIVATIVE; TEICOPLANIN; TELEVANCIN; TIGECYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANEMIA; ANTIBIOTIC RESISTANCE; ARTHRALGIA; BACTERICIDAL ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HOSPITAL INFECTION; HUMAN; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SHORT SURVEY; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; HUMANS; METHICILLIN RESISTANCE; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCUS AUREUS;

EID: 34249888190     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.02.011     Document Type: Short Survey

References (62)

1. Peacock S.J., de Silva I., and Lowy F.D. What determines nasal carriage of Staphylococcus aureus?. Trends Microbiol 9 (2001) 605-610
2. Chastre J., and Fagon J.Y. Ventilator associated pneumonia. Am J Respir Crit Care Med 165 (2002) 860-903
3. Rello J., Torres A., Ricart M., et al. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 150 (1994) 1545-1549
4. Pujol M., Corbella X., Pena C., et al. Clinical and epidemiological findings in mechanically-ventilated patients with methicillin-resistant Staphylococcus aureus pneumonia. Eur J Clin Microbiol Infect Dis 17 (1998) 622-628
5. Combes A., Luyt C.E., Fagon J.Y., et al. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 170 (2004) 786-792
6. DeRyke C.A., Lodise Jr. T.P., Rybak M.J., and McKinnon P.S. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 128 (2005) 1414-1422
7. Gonzales C., Rubio M., Romero-Vivas J., Gonzales M., and Picazo J.J. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 29 (1999) 1171-1177
8. Kollef M.H., Sherman G., Ward S., and Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115 (1999) 462-474
9. Francis J.S., Doherty M.C., Lopatin U., et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 40 (2005) 100-107
10. Kowalsky T.J., Berbari E.F., and Osmon D.R. Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infections. Mayo Clin Proc 80 (2005) 1201-1208
11. Kluytmans-Vandenbergh M.F., and Kluytmans J.A. Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin Microbiol Infect 12 Suppl. 1 (2006) 9-15
12. Huskins W.C., and Goldmann D.A. Controlling methicillin-resistant Staphylococcus aureus, aka 'Superbug'. Lancet 365 (2005) 273-275
13. European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2004. http://www.rivm.nl/earss/Images/EARSS%20annual%20report%202004%20webversie_tcm61-25345.pdf [accessed 11 October 2006].
14. Menichetti F. Current and emerging serious Gram-positive infections. Clin Microbiol Infect 11 Suppl. 3 (2005) 22-28
15. Tiemersma E.W., Bronzwaer S.L., Lyytikainen O., et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 10 (2004) 1627-1634
16. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-June 2001, issued August 2001. Am J Infect Control 2001; 29:404-21.
17. Foster T.J. The Staphylococcus aureus 'superbug'. J Clin Invest 114 (2004) 1693-1696
18. Jevons M.P. 'Celbenin'-resistant staphylococci. BMJ 1 (1961) 124-125
19. Lowy F.D. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 111 (2003) 1265-1273
20. Hiramatsu K., Okuma K., Xue Ma X., Yamamoto M., Hori S., and Kapi M. New trends in Staphylococcus aureus infections: glycopeptide resistance in hospital and methicillin-resistance in the community. Curr Opin Infect Dis 15 (2002) 407-413
21. Ito T., Ma X.X., Takeuchi F., Okuma K., Yuzawa H., and Hiramatsu K. Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemother 48 (2004) 2637-2651
22. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., and Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40 (1997) 135-146
23. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. Villanova, PA: NCCLS; 2003.
24. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:765-6. [Erratum. MMWR Morb Mortal Wkly Rep 1997;46:851.].
25. Ploy M.C., Grelaud C., Martin C., et al. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351 (1998) 1212
26. Kim M.N., Pai C.H., Woo J.H., et al. Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol 38 (2000) 3879-3881
27. Oliveira G.A., Dell'Aquila A.M., Masiero R.L., et al. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect Control Hosp Epidemiol 22 (2001) 443-448
28. Song J.H., Hiramatsu K., Suh J.Y., et al. Asian Network for Surveillance of Resistant Pathogens Study Group. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 48 (2004) 4926-4928
29. Sieradzki K., Roberts R.B., Haber S.W., and Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 340 (1999) 517-523
30. Smith T.L., Pearson M.L., Wilcox K.R., et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 340 (1999) 493-501
31. Centers for Disease Control and Prevention (CDC). Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002;51:902.
32. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-7.
33. Ferraz V., Duse A.G., Kassel M., et al. Vancomycin-resistant Staphylococcus aureus occurs in South Africa. S Afr Med J 90 (2000) 1113
34. Centers for Disease Control and Prevention (CDC). VISA/VRSA: vancomycin intermediate/resistant Staphylococcus aureus. Fact sheet 1 April 2003. http://www.cdc.gov/ncidod/dhqp/ar_visavrsa_FAQ.html [accessed on 6 January 2004].
35. Cosgrove S.E., Carroll K.C., and Perl T.M. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 39 (2004) 539-545
36. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416
37. Cruciani M., Gatti G., Lazzarini L., et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 35 (1996) 865-871
38. Lamer C., de Beco V., Soler P., et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 37 (1993) 281-286
39. Kollef M.H. Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection. Eur J Clin Microbiol Infect Dis 24 (2005) 794-803
40. Kitzis M.D., and Goldstein F.W. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect 12 (2006) 92-95
41. Wysocki M., Delatour F., Faurisson F., et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomised study. Antimicrob Agents Chemother 45 (2001) 2460-2467
42. Rello J., Sole-Violan J., Sa-Borges M., et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 33 (2005) 1983-1987
43. Anstead G.M., and Owens A.D. Recent advances in the treatment of infections due to resistant Staphylococcus aureus. Curr Opin Infect Dis 17 (2004) 549-555
44. Schmidt-Joanas M., de Roux A., and Lode H. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient. Curr Opin Crit Care 11 (2005) 481-486
45. Noskin G.A. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 41 Suppl. 5 (2005) S303-S314
46. Patterson J.E. New Gram-positive agents in nosocomial infection. Curr Opin Infect Dis 13 (2000) 593-598
47. Nasaraway S.A., Short A.F., Kuter D.J., et al. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 37 (2003) 1609-1616
48. Segreti J. Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance. Clin Microbiol Infect 11 Suppl. 3 (2005) 29-35
49. Frippiat F., Bergiers C., Michel C., et al. Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother 53 (2004) 1114-1115
50. Legout L., Senneville E., Gomel J.J., et al. Linezolid induced neuropathy. Clin Infect Dis 38 (2004) 767-768
51. Wunderink R.G., Rello J., Cammarata S.K., Croos-Dabrera R.V., and Kollef M.H. Linezolid vs vancomycin: analysis of double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124 (2003) 1789-1797
52. Kollef M.H., Rello J., Cammarata S.K., et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia. Retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30 (2004) 388-394
53. Conte Jr. J.E., Golden J.A., Kipps J., and Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 46 (2002) 1475-1480
54. Shorr A.F., Susla G.M., and Kollef M.H. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 32 (2004) 137-143
55. Mullins C.D., Kuznik A., Shaya F.T., et al. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Ther 28 (2006) 1184-1198
56. Peeters M.J., and Sarria J.C. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci 330 (2005) 102-104
57. Lomaestro B.M. Resistance to linezolid. Are we surprised? How hard should we look?. Ann Pharmacother 37 (2003) 909-911
58. Yanagihara K., Okada M., Fukuda Y., et al. Efficacy of quinupristin-dalfopristin against methicillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of hematogenous pulmonary infection. Chemotherapy 50 (2004) 260-264
59. Fagon J., Patrick H., Haas D.W., et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomised comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 161 (2000) 753-762
60. De Robertis E., Viscidi D., Servillo G., et al. Use of quinupristin-dalfopristin in a critical patient with a methicillin-resistant Staphylococcus aureus infection. Minerva Anestesiol 70 (2004) 747-749
61. Raad I., Hachem R., Hanna H., et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 53 (2004) 646-649
62. Streit J.M., Jones R.N., Sader H.S., and Fritsche T.R. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 24 (2004) 111-118